IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation.
Langrehr
J M
JM
Department of Surgery, Charité Campus Virchow-Klinikum, Humboldt University Berlin, Berlin, Germany.
Lohmann
R
R
Guckelberger
O
O
Müller
A R
AR
Raakow
R
R
Nüssler
N C
NC
Klupp
J
J
Pfitzmann
R
R
Jonas
S
S
Settmacher
U
U
Steinmüller
T
T
Neuhaus
P
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D012306:Risk; D016559:Tacrolimus / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; C079843:inolimomab; D016559:Tacrolimus